Efficacy and safety of Ivarmacitinib in moderate-to-severe atopic dermatitis patients with or without previous systemic treatments: a post-hoc analysis of a phase III trial
<p>Prior exposure to systemic treatments may affect treatment outcomes in moderate-to-severe atopic dermatitis (AD).</p> <p>This study aimed to explore the efficacy and safety of Ivarmacitinib (SHR0302) in moderate-to-severe AD patients with or without previous systemic treatments....
Saved in:
| 主要作者: | |
|---|---|
| 其他作者: | , , , , , , , , , |
| 出版: |
2025
|
| 主题: | |
| 标签: |
添加标签
没有标签, 成为第一个标记此记录!
|
